Maintenance of remission in ulcerative colitis. Effect of an orally absorbed mast cell stabilizer.
PRD-92 a well-absorbed mast cell stabilizer was examined in patients with ulcerative colitis by a double-blind controlled trial. Forty-three patients who were in clinical remission or PRD-92 for six months. Relapses occurred in 42% of patients on PRD-92 and 24% on sulfasalazine. PRD-92 has a less prophylactic effect than sulfasalazine in ulcerative colitis.